Evidence map›Paper›PMID 35701672›Full record

ArticleNature genetics2022

Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Malgorzata Gozdecka, Eshwar Meduri, Milena Mazan, Konstantinos Tzelepis, Monika Dudek, Andrew J Knights, Mercedes Pardo, Lu Yu, Jyoti S Choudhary, Emmanouil Metzakopian and 17 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Malgorzata GozdeckaHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Eshwar MeduriWellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
Milena MazanHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Konstantinos TzelepisHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0002-4865-7648
Monika DudekHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Andrew J KnightsGenomics of Gene Regulation, Wellcome Trust Sanger Institute, Hinxton, UK.
Mercedes PardoProteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0002-3477-9695
Lu YuProteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0001-8378-9112
Jyoti S ChoudharyProteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Emmanouil MetzakopianMouse Genomics, Wellcome Trust Sanger Institute, Hinxton, UK.
Vivek IyerExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Haiyang YunWellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
Naomi ParkSequencing Research Group, Wellcome Trust Sanger Institute, Cambridge, UK.
Ignacio VarelaInstituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan), Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain.ORCID http://orcid.org/0000-0002-0969-506X
Ruben BautistaNew Pipeline Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Grace CollordHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0003-1924-4411
Oliver DoveyHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Dimitrios A GaryfallosHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Etienne De BraekeleerHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Saki KondoLaboratory of Molecular Genetics, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Jonathan CooperHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
Berthold GöttgensCambridge Institute for Medical Research and Wellcome Trust-Medical Research Council, Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-6302-5705
Lars BullingerDepartment of Internal Medicine III, Ulm University Medical Centre, Ulm, Germany.
Paul A NorthcottDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
David AdamsExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
George S VassiliouHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK. gsv20@sanger.ac.uk.ORCID http://orcid.org/0000-0003-4337-8022
Brian J P HuntlyWellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK. bjph2@cam.ac.uk.ORCID http://orcid.org/0000-0003-0312-161X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35701672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.